The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMAB | +230.08% | -89.21% | -35.92% | -65% |
| S&P | +16.23% | +94.45% | +14.22% | +102% |
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $191.04M | 0.0% |
| Net Income | -$5.52M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $165.41M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.63M | 0.0% |
| Short Term Debt | $0.85M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -37.50% | 0.0% |
| Metric | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|
| Price to Book | 0.27 | 1.00 | - |
| Price to Tangible Book Value | 0.27 | 0.96 | - |
| Total Debt | $3.68M | $3.48M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
